Table 2.

Overview of ongoing trials involving FGFR inhibitors (alone or in combination) in urothelial carcinoma.

Drug	Therapeutic scheme	FGFR status	Phase	Setting	Estimated Enrollment (n° participants)	Recruitment Status	Primary endpoints	ClinicalTrials.gov identifier
Erdafitinib	Erdafitinib + JNJ-63723283	Selected FGFR gene aberrations	Ib/II	⩾1 line	102	Recruiting	phase Ib: DLT AEs phase II: ORR AEs	NCT03473743
	Erdafitinib versus vinflunine or docetaxel or pembrolizumab	Selected FGFR gene aberrations (based on Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay)	III	⩾1 line	631	Recruiting	OS	NCT03390504
Rogaratinib	Rogaratinib + atezolizumab	High FGFR1 or 3 mRNA expression levels	Ib/II	No prior systemic treatment and ineligibility for cisplatin-based	210	Recruiting	phase Ib: DLTs, TEAEs TESAEs phase II: PFS	NCT03473756
	Rogaratinib versus chemotherapy	FGFR1 or 3 positive	II/III	⩾1 line	175a	Active, not recruiting	OS	NCT03410693
Vofatamab	Vofatamab + pembrolizumab	-	Ib/II	PD during or following platinum-containing chemotherapy	74	Recruiting	DLTs Safety and tolerability of vofatamab + pembrolizumab ORR	NCT03123055
	Vofatamab ± docetaxel, Or versus docetaxe l	FGFR3 mutant/fusion	I/II(b)	⩾1 line which has not included taxane	300	Active, not recruiting	PFS	NCT02401542

^aActual enrollment.

AEs, adverse events; DLTs, dose-limiting toxicities; OS, overall survival; PD, progression disease; PFS, progression free survival; TEAEs, treatment-emergent adverse events; TESAEs, treatment-emergent serious adverse events.